Review

mouse anti human trka (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems mouse anti human trka
Mouse Anti Human Trka, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+human+trka/pmc10742157-101-37-41?v=R%26D+Systems
Average 92 stars, based on 2 article reviews

mouse anti human trka - by Bioz Stars, 2026-07

92/100 stars

Images

Image Search Results

( a ) Indirect IFs demonstrating increased overlapping (yellow/orange) immunoreactivity for TrkA (green) and MitoTracker-labeled mitochondria (red) (upper panels) and Y490 phosphorylated TrkAIII (pTrkAIII, green) and MitoTracker-labeled mitochondria (red) (lower panels) in DTT-treated (5 mM for 6 h) TrkAIII SH-SY5Y cells compared to untreated controls (control). DAPI stained nuclei are blue. (bar = 50 μm). ( b ) Western blots demonstrating TrkAIII cleavage and Y674/5 phosphorylation in mitochondria (50 mg) from DTT-treated (5 mM for 6 h) TrkAIII SH-SY5Y cells compared to untreated TrkAIII SH-SY5Y controls. ( c ) Western blots demonstrating increased PTPase oxidation (arrows) in mitochondria (50 mg) from DTT-treated TrkAIII SH-SY5Y cells (5 mM for 6 h) compared to untreated controls (Con). ( d ) Phase contrast images merged with green fluorescence and histogram demonstrating significant differences (* p < 0.0001) in pcDNA-SH-SY5Y and TrkAIII SH-SY5Y percentage cell death at 24 h and 48 h, induced by 5 mM DTT.

Journal: International Journal of Molecular Sciences

Article Title: Molecular Characterization and Inhibition of a Novel Stress-Induced Mitochondrial Protecting Role for Misfolded TrkAIII in Human SH-SY5Y Neuroblastoma Cells

doi: 10.3390/ijms25105475

Figure Lengend Snippet: ( a ) Indirect IFs demonstrating increased overlapping (yellow/orange) immunoreactivity for TrkA (green) and MitoTracker-labeled mitochondria (red) (upper panels) and Y490 phosphorylated TrkAIII (pTrkAIII, green) and MitoTracker-labeled mitochondria (red) (lower panels) in DTT-treated (5 mM for 6 h) TrkAIII SH-SY5Y cells compared to untreated controls (control). DAPI stained nuclei are blue. (bar = 50 μm). ( b ) Western blots demonstrating TrkAIII cleavage and Y674/5 phosphorylation in mitochondria (50 mg) from DTT-treated (5 mM for 6 h) TrkAIII SH-SY5Y cells compared to untreated TrkAIII SH-SY5Y controls. ( c ) Western blots demonstrating increased PTPase oxidation (arrows) in mitochondria (50 mg) from DTT-treated TrkAIII SH-SY5Y cells (5 mM for 6 h) compared to untreated controls (Con). ( d ) Phase contrast images merged with green fluorescence and histogram demonstrating significant differences (* p < 0.0001) in pcDNA-SH-SY5Y and TrkAIII SH-SY5Y percentage cell death at 24 h and 48 h, induced by 5 mM DTT.

Article Snippet: Mouse monoclonal anti-human TrkA (B3, sc-7268), rabbit polyclonal anti-human XIAP (H-202), rabbit polyclonal anti-human α-tubulin (H-3000) and monoclonal mouse anti-human calmodulin (sc-137079) antibodies were from SantaCruz (Santa Cruz, CA, USA).

Techniques: Labeling, Control, Staining, Western Blot, Phospho-proteomics, Fluorescence

( a ) Western blots demonstrating differences in TrkAIII immunoreactivity in untreated (CON) and DTT-treated (5 mM DTT for 1, 2 and 3 h) TrkAIII SH-SY5Y cell extracts (30 mg) under non-reducing and reducing conditions. ( b ) Co-immunoprecipitation Western blots demonstrating increased TrkAIII pulldown of Grp78 by anti-TrkA antibody in DTT-treated (5 mM for 6 h) TrkAIII SH-SY5Y cell extracts compared to untreated control extracts (CON) and similar levels of TrkAIII immunoprecipitated by anti-TrkA antibody but not by pre-immune mouse IgG in untreated (Con) and DTT-treated (5 mM for 6 h) TrkAIII SH-SY5Y cell extracts (500 μg), plus the absence of GRP78 or TrkA isoform pulldown by anti-TrkA antibody in pcDNA-SH-SY5Y cell extracts (500 μg). ( c ) Western blots of TrkAIII pulldown by calmodulin-conjugated Sepharose (CaM-Seph) in TrkAIII SH-SY5Y but not pcDNA-SH-SY5Y cell extracts (500 μg) in the presence of 150 mM CaCl 2 (left panel) plus increased TrkAIII pulldown by calmodulin-conjugated Sepharose (CaM-Seph) in TrkAIII SH-SY5Y cell extracts (500 μg) in the presence of 150 μM CaCl 2 compared to 5 mM EGTA (right panel), plus no TrkAIII pulldown by unconjugated Sepharose in TrkAIII SH-SY5Y cell extracts in the presence of 150 μM CaCl 2 or 5 mM EGTA (right panel). ( d ) Co-immunoprecipitation Western blots demonstrating enhanced pulldown of TrkAIII by anti-calmodulin antibody (anti-CaM) but not by pre-immune mouse IgG in DTT-treated (5 mM for 3 and 6 h) but not untreated (Con) TrkAIII SH-SY5Y extracts (500 μg) (upper left panels) and calmodulin pulldown by anti-calmodulin antibody (anti-CaM) but not pre-immune IgG in untreated (Con) and DTT-treated (DTT) TrkAIII SH-SY5Y cell extracts (500 μg) (upper right panels), plus no pulldown of TrkAIII by anti-calmodulin antibody in pcDNA-SH-SY5Y extracts (500 μg).

Journal: International Journal of Molecular Sciences

Article Title: Molecular Characterization and Inhibition of a Novel Stress-Induced Mitochondrial Protecting Role for Misfolded TrkAIII in Human SH-SY5Y Neuroblastoma Cells

doi: 10.3390/ijms25105475

Figure Lengend Snippet: ( a ) Western blots demonstrating differences in TrkAIII immunoreactivity in untreated (CON) and DTT-treated (5 mM DTT for 1, 2 and 3 h) TrkAIII SH-SY5Y cell extracts (30 mg) under non-reducing and reducing conditions. ( b ) Co-immunoprecipitation Western blots demonstrating increased TrkAIII pulldown of Grp78 by anti-TrkA antibody in DTT-treated (5 mM for 6 h) TrkAIII SH-SY5Y cell extracts compared to untreated control extracts (CON) and similar levels of TrkAIII immunoprecipitated by anti-TrkA antibody but not by pre-immune mouse IgG in untreated (Con) and DTT-treated (5 mM for 6 h) TrkAIII SH-SY5Y cell extracts (500 μg), plus the absence of GRP78 or TrkA isoform pulldown by anti-TrkA antibody in pcDNA-SH-SY5Y cell extracts (500 μg). ( c ) Western blots of TrkAIII pulldown by calmodulin-conjugated Sepharose (CaM-Seph) in TrkAIII SH-SY5Y but not pcDNA-SH-SY5Y cell extracts (500 μg) in the presence of 150 mM CaCl 2 (left panel) plus increased TrkAIII pulldown by calmodulin-conjugated Sepharose (CaM-Seph) in TrkAIII SH-SY5Y cell extracts (500 μg) in the presence of 150 μM CaCl 2 compared to 5 mM EGTA (right panel), plus no TrkAIII pulldown by unconjugated Sepharose in TrkAIII SH-SY5Y cell extracts in the presence of 150 μM CaCl 2 or 5 mM EGTA (right panel). ( d ) Co-immunoprecipitation Western blots demonstrating enhanced pulldown of TrkAIII by anti-calmodulin antibody (anti-CaM) but not by pre-immune mouse IgG in DTT-treated (5 mM for 3 and 6 h) but not untreated (Con) TrkAIII SH-SY5Y extracts (500 μg) (upper left panels) and calmodulin pulldown by anti-calmodulin antibody (anti-CaM) but not pre-immune IgG in untreated (Con) and DTT-treated (DTT) TrkAIII SH-SY5Y cell extracts (500 μg) (upper right panels), plus no pulldown of TrkAIII by anti-calmodulin antibody in pcDNA-SH-SY5Y extracts (500 μg).

Techniques: Western Blot, Immunoprecipitation, Control

( a ) Western blots demonstrating TrkAIII cleavage and phosphorylation in mitochondria (50 μg) from TrkAIII SH-SY5Y cells treated with 5 mM DTT alone for 6 h and in mitochondria from TrkAIII SH-SY5Y cells co-treated with 5 mM DTT and either HA-15 (20 μM) (DTT/HA); brefeldin A (5 mg/mL) (DTT/BfA) or W7 (60 μM) (DTT/W7) plus non-phosphorylated TrkAIII in mitochondria from untreated TrkAIII SH-SY5Y cells (Con) and lack of TrkA or phosphorylated TrkA immunoreactivity in mitochondria (50 μg) from untreated (Con) and DTT-treated (5 mm for 6 h) pcDNA-SH-SY5Y cells. ( b ) Line graphs demonstrating significant inhibition (*) of pcDNA-SH-SY5Y and TrkAIII SH-SY5Y proliferation by BfA (5 μg/mL) and W7 (60 μM) but not by HA-15 (20 μM) at 24 and 48 h (* p < 0.0001). ( c ) Phase contrast images merged with green fluorescence plus histograms demonstrating percentage pcDNA-SH-SY5Y and TrkAIII SH-SY5Y cell death induced by 5 mM DTT alone (DTT), DTT and either HA-15 (20 μM) (DTT/HA), BfA (5 μg/mL) (DTT/BfA) or W7 (60 μM) (DTT/W7), plus pcDNA-SH-SY5Y and TrkAIII SH-SY5Y cell death induced by W7 (60 μM) alone (W7) at 24 and 48 h (* p < 0.006).

Journal: International Journal of Molecular Sciences

Article Title: Molecular Characterization and Inhibition of a Novel Stress-Induced Mitochondrial Protecting Role for Misfolded TrkAIII in Human SH-SY5Y Neuroblastoma Cells

doi: 10.3390/ijms25105475

Figure Lengend Snippet: ( a ) Western blots demonstrating TrkAIII cleavage and phosphorylation in mitochondria (50 μg) from TrkAIII SH-SY5Y cells treated with 5 mM DTT alone for 6 h and in mitochondria from TrkAIII SH-SY5Y cells co-treated with 5 mM DTT and either HA-15 (20 μM) (DTT/HA); brefeldin A (5 mg/mL) (DTT/BfA) or W7 (60 μM) (DTT/W7) plus non-phosphorylated TrkAIII in mitochondria from untreated TrkAIII SH-SY5Y cells (Con) and lack of TrkA or phosphorylated TrkA immunoreactivity in mitochondria (50 μg) from untreated (Con) and DTT-treated (5 mm for 6 h) pcDNA-SH-SY5Y cells. ( b ) Line graphs demonstrating significant inhibition (*) of pcDNA-SH-SY5Y and TrkAIII SH-SY5Y proliferation by BfA (5 μg/mL) and W7 (60 μM) but not by HA-15 (20 μM) at 24 and 48 h (* p < 0.0001). ( c ) Phase contrast images merged with green fluorescence plus histograms demonstrating percentage pcDNA-SH-SY5Y and TrkAIII SH-SY5Y cell death induced by 5 mM DTT alone (DTT), DTT and either HA-15 (20 μM) (DTT/HA), BfA (5 μg/mL) (DTT/BfA) or W7 (60 μM) (DTT/W7), plus pcDNA-SH-SY5Y and TrkAIII SH-SY5Y cell death induced by W7 (60 μM) alone (W7) at 24 and 48 h (* p < 0.006).

Techniques: Western Blot, Phospho-proteomics, Inhibition, Fluorescence

Figure 2. Nerve growth factor (NGF) receptors in the ejaculated sperm, epididymis and testis of fertile men. (A) The bar graph shows the mean and standard deviation of the fold increase in TrKA (slanted-line bar graph) and p75NTR (checkerboard bar graph) messenger RNA (mRNA) levels in fertile men (n = 7). (B,C) The plots (blue gate) display the ﬂow cytometric analysis (representative of

Journal: Biomedicines

Article Title: A Possible Role for Nerve Growth Factor and Its Receptors in Human Sperm Pathology.

doi: 10.3390/biomedicines11123345

Figure Lengend Snippet: Figure 2. Nerve growth factor (NGF) receptors in the ejaculated sperm, epididymis and testis of fertile men. (A) The bar graph shows the mean and standard deviation of the fold increase in TrKA (slanted-line bar graph) and p75NTR (checkerboard bar graph) messenger RNA (mRNA) levels in fertile men (n = 7). (B,C) The plots (blue gate) display the ﬂow cytometric analysis (representative of

Article Snippet: After washing three times in PBS supplemented with BSA, sperm were incubated at 4 ◦C for 1 h in PBS/BSA containing FITC-labelled rabbit anti-human p75NTR extracellular domain (ANT-007-F, Alomone Labs, Jerusalem, Israel) (10 mL/sample) and PE-labelled mouse anti-human TrKA (FAB1751P, R&D Systems, Minneapolis, MN, USA) (10 mL/sample).

Techniques: Standard Deviation

Figure 3. Nerve growth factor (NGF) receptors in altered sperm from men with infertility. (A–D) Fluorescence immunostaining of human sperm from men with infertility (varicocele (V) or uro- genital infections (UGIs)) incubated with the anti-TrKA (A,B) and anti-p75NTR (C,D) antibodies. In (A)

Journal: Biomedicines

Article Title: A Possible Role for Nerve Growth Factor and Its Receptors in Human Sperm Pathology.

doi: 10.3390/biomedicines11123345

Figure Lengend Snippet: Figure 3. Nerve growth factor (NGF) receptors in altered sperm from men with infertility. (A–D) Fluorescence immunostaining of human sperm from men with infertility (varicocele (V) or uro- genital infections (UGIs)) incubated with the anti-TrKA (A,B) and anti-p75NTR (C,D) antibodies. In (A)

Techniques: Fluorescence, Immunostaining, Incubation

FIGURE 1 | (A) Medium NGF levels in PBMC-treated (20 mg/ml or 20 pg/ml of ALP) or untreated cells. Description of what is contained in the ﬁrst panel; (B) TrKA and (C) p75NTR Facs analysis of PBMC-treated (20 mg/ml or 20 pg/ml of ALP) or untreated cells. CTR, control; EtOH, alprostadil in ethanol; ALP, alprostadil.

Journal: Frontiers in Urology

Article Title: The Role of NGF and Its Receptor TrKA in Patients With Erectile Dysfunction

doi: 10.3389/fruro.2022.860612

Figure Lengend Snippet: FIGURE 1 | (A) Medium NGF levels in PBMC-treated (20 mg/ml or 20 pg/ml of ALP) or untreated cells. Description of what is contained in the ﬁrst panel; (B) TrKA and (C) p75NTR Facs analysis of PBMC-treated (20 mg/ml or 20 pg/ml of ALP) or untreated cells. CTR, control; EtOH, alprostadil in ethanol; ALP, alprostadil.

Article Snippet: The following fluorochrome-labeled mAbs were used to identify TrKA and p75NTR receptors onWBCs: FITClabeled rabbit anti-human p75NTR extracellular domain (#ANT007-F, Alomone Labs) and PE-labeled mouse anti-human TrKA (FAB1751P, R&D Systems).

Techniques: Control

FIGURE 4 | (A) Colorimetric analysis of total thiol in plasma of ED patients. Cubital vein of healthy subjects (CV-CTRL), cubital vein (CV) or corpus cavernosum (CC) of ED patients after alprostadil (ALP) injection (CV+ALP), and CC after ALP (CC+ALP). Horizontal bars indicate mean values. ***p < 0.0001. Comparisons between the groups were made using one-way ANOVA followed by Bonferroni multiple comparison tests. (B) Correlation between TrKA+ cells and thiol levels in CC-ED. r, Pearson index; r2, coefﬁcient of determination.

Journal: Frontiers in Urology

Article Title: The Role of NGF and Its Receptor TrKA in Patients With Erectile Dysfunction

doi: 10.3389/fruro.2022.860612

Figure Lengend Snippet: FIGURE 4 | (A) Colorimetric analysis of total thiol in plasma of ED patients. Cubital vein of healthy subjects (CV-CTRL), cubital vein (CV) or corpus cavernosum (CC) of ED patients after alprostadil (ALP) injection (CV+ALP), and CC after ALP (CC+ALP). Horizontal bars indicate mean values. ***p < 0.0001. Comparisons between the groups were made using one-way ANOVA followed by Bonferroni multiple comparison tests. (B) Correlation between TrKA+ cells and thiol levels in CC-ED. r, Pearson index; r2, coefﬁcient of determination.

Techniques: Clinical Proteomics, Injection, Comparison

FIGURE 3 | FACS analysis of TrKA in blood withdrawals of ED patients. (A) Percentage of TrKA+ cells; (B) MFI: mean ﬂuorescent intensity. Cubital vein of healthy subjects (CV-CTRL), cubital vein (CV) or corpus cavernosum (CC) of ED patients after Alprostadil (ALP) injection (CV+ALP), and CC after ALP (CC+ALP). Horizontal bars indicate mean values. ***p < 0.0001; **p < 0.001; *p < 0.01. Comparisons between the groups were made using one-way ANOVA followed by Bonferroni multiple comparison tests. CV-CTRL.

Journal: Frontiers in Urology

Article Title: The Role of NGF and Its Receptor TrKA in Patients With Erectile Dysfunction

doi: 10.3389/fruro.2022.860612

Figure Lengend Snippet: FIGURE 3 | FACS analysis of TrKA in blood withdrawals of ED patients. (A) Percentage of TrKA+ cells; (B) MFI: mean ﬂuorescent intensity. Cubital vein of healthy subjects (CV-CTRL), cubital vein (CV) or corpus cavernosum (CC) of ED patients after Alprostadil (ALP) injection (CV+ALP), and CC after ALP (CC+ALP). Horizontal bars indicate mean values. ***p < 0.0001; **p < 0.001; *p < 0.01. Comparisons between the groups were made using one-way ANOVA followed by Bonferroni multiple comparison tests. CV-CTRL.

Techniques: Injection, Comparison

( A-I ) Fluorescent immunohistochemistry on representative horizontal sections from E12.5 Control ( A-C , N = 3) or Elp1 CKO ( D-I , N = 3) revealing expression of TrkA (purple) with TUNEL staining (green). ( G-I ) Higher magnification of boxed regions in D-F . Arrowheads point to TrkA neurons that are TUNEL- positive ( G-I ). ( J ) Quantification of TrkA-, TrkB-, and TrkC-expressing neurons at E13.5 in Control (blue, N = 3) and Elp1 CKO (orange, N = 3) trigeminal ganglia. Values are mean ± SEM. *p = 0.016, unpaired t-test adjusted for multiple comparisons using Holm-Sidak method. Scale bars: 50µm ( A ), applies to B-F ; 20µm ( G ), applies to H-I .

Journal: bioRxiv

Article Title: Loss of Elp1 disrupts trigeminal ganglion neurodevelopment in a model of Familial Dysautonomia

doi: 10.1101/2021.06.10.447739

Figure Lengend Snippet: ( A-I ) Fluorescent immunohistochemistry on representative horizontal sections from E12.5 Control ( A-C , N = 3) or Elp1 CKO ( D-I , N = 3) revealing expression of TrkA (purple) with TUNEL staining (green). ( G-I ) Higher magnification of boxed regions in D-F . Arrowheads point to TrkA neurons that are TUNEL- positive ( G-I ). ( J ) Quantification of TrkA-, TrkB-, and TrkC-expressing neurons at E13.5 in Control (blue, N = 3) and Elp1 CKO (orange, N = 3) trigeminal ganglia. Values are mean ± SEM. *p = 0.016, unpaired t-test adjusted for multiple comparisons using Holm-Sidak method. Scale bars: 50µm ( A ), applies to B-F ; 20µm ( G ), applies to H-I .

Article Snippet: Primary antibodies used included the following: Elp1 (Sigma #SAB2701068, 1:500), β- tubulin III (Abcam #ab78078, 1:1000 for sections, 1:300 for whole-mount), Sox10 (R&D #AF2864, 1:200 or GeneTex #GTX128374, 1:500), TrkA (R&D #AF1056, 1:500 for sections, 1:200 for whole-mount), TrkB (R&D #AF1494, 1:300), TrkC (R&D #AF1404, 1:300), Six1 (Sigma #HPA001893, 1:500), Islet1 (DSHB #PCRP-ISL1-1A9, 1:500), Neuropilin2 (R&D cat. AF567, 1:500), and Pax3 (DSHB, “Pax3”, 1:200).

Techniques: Immunohistochemistry, Expressing, TUNEL Assay, Staining

( A-O ) Fluorescent immunohistochemistry on representative horizontal sections from E11.5 ( A-F ) and E12.5 ( G-O ) Control ( A- L , N=2 each) or Elp1 CKO ( M-O , N=2) mouse embryos demonstrating expression of TrkA ( A, D, G, J, M-O , green), TrkB ( B, E, H, K , green), TrkC ( C, F, I, L , green), and Six1 ( D-F, J-L , N-O , red). Arrowheads point to neurons that co- express Six1 with TrkA ( D, J, N, O ), TrkB ( E ), or TrkC ( F ). Scale bars: 100µm ( A ), applies to B-C, G-I, M ; 20µm ( D ), applies to E-F, J- L, N-O .

Journal: bioRxiv

Article Title: Loss of Elp1 disrupts trigeminal ganglion neurodevelopment in a model of Familial Dysautonomia

doi: 10.1101/2021.06.10.447739

Figure Lengend Snippet: ( A-O ) Fluorescent immunohistochemistry on representative horizontal sections from E11.5 ( A-F ) and E12.5 ( G-O ) Control ( A- L , N=2 each) or Elp1 CKO ( M-O , N=2) mouse embryos demonstrating expression of TrkA ( A, D, G, J, M-O , green), TrkB ( B, E, H, K , green), TrkC ( C, F, I, L , green), and Six1 ( D-F, J-L , N-O , red). Arrowheads point to neurons that co- express Six1 with TrkA ( D, J, N, O ), TrkB ( E ), or TrkC ( F ). Scale bars: 100µm ( A ), applies to B-C, G-I, M ; 20µm ( D ), applies to E-F, J- L, N-O .

Techniques: Immunohistochemistry, Expressing

Review

Structured Review

Images

Similar Products

Image Search Results